Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT

Inclusion Criteria:

• Age ≥12 years old, male or female;

• Patients diagnosed with hematological malignancies and undergoing UCBT;

• ECOG score ≤2;

• Voluntary participation in this clinical trial, patients fully understand the trialcontent and sign the informed consent

Exclusion Criteria:

• Pregnant or lactating women；

• Known allergy to Romiplostim N01;

• A history of severe thrombotic events or known risk factors for thrombosis or activethromboembolism requiring anticoagulation;

• A history of platelet dysfunction or bleeding prone disease or severe bleeding (requiring more than 2 units of red blood cell infusion or a hematocrit drop of ≥10%) within 7 days prior to screening;

• Chronic active hepatitis B and C;

• Repeat or multiple transplantation or multiple organ transplantation;

• HIV positive, EBV-DNA positive, CMV-DNA positive;

• Have severe infection or complicated with serious heart, liver, lung, kidney,neurological or metabolic diseases;

• A serious adverse event (Level 4 or 5) as defined by the Standard GeneralTerminology for Adverse Events Version 4.0 occurred during the pre-treatment period;

• Participants participate in another clinical study with any exploratory drug ordevice within 30 days prior to baseline visit; Observational studies are allowed;

• Subjects with cognitive impairment or uncontrolled mental illness;

• Subjects and/or authorized family members to refuse treatment with Romiplostim N01;

• Those who are judged by the researchers as not suitable for inclusion (such asaccompanying medical history, which may affect the safety of the subjects or it isestimated that the treatment cannot be adhered to due to financial problems).